Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
  • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the invention relates to the combination of certain known active compounds for therapeutic purposes.
• the substances used in the combination according to the invention are a known active compound from the PDE inhibitors class and an active compound from the ⁇ 2 adrenoceptor agonists class. Their combined use in the sense according to the invention for therapeutic purposes has not yet been described in the prior art.
• the invention relates to compositions and methods for preventing or reducing the onset of symptoms of pulmonary diseases, or treating or reducing the severity of pulmonary diseases.
• PDE4 phosphodiesterase 4
• the invention relates in a first aspect to a method for preventing or reducing the onset of symptoms of a pulmonary disease, or treating or reducing the severity of a pulmonary disease by administering to a patient in need thereof an effective amount of roflumilast and formoterol either in a single combined form, separately, or separately and sequentially where the sequential administration is close in time, or remote in time.
• the invention also relates to a composition for preventing or reducing the onset of symptoms of a pulmonary disease, or treating or reducing the severity of a pulmonary disease comprising an effective amount of roflumilast, an effective amount of formoterol and a pharmaceutically acceptable excipient.
• the invention additionally relates to a method for preparing a composition which is effective for preventing or reducing the onset of symptoms of a pulmonary disease, or treating or reducing the severity of a pulmonary disease, which method comprises mixing an effective amount of roflumilast and formoterol with a pharmaceutically acceptable excipient.
• the combination therapy which is the subject matter of this invention comprises administering roflumilast with formoterol to prevent onset of a pulmonary disease event or to treat an existing condition.
• the two compounds may be administered together in a single dosage form. Or they may be administered in different dosage forms. They may be administered at the same time. Or they may be administered both close in time or remotely, such as where one drug is administered in the morning and the second drug is administered in the evening.
• the combination may be used prophylactically or after the onset of symptoms has occurred. In some instances the combination may be used to prevent the progression of a pulmonary disease or to arrest the decline of a function such as lung function.
• the invention thus relates to the combined use of roflumilast and formoterol in preventing the symptoms of, or treating a respiratory tract disorder.
• roflumilast is understood to include the pharmacologically acceptable salts and the N-oxide of roflumilast, which can likewise be used according to the invention.
• formoterol is understood in connection with this invention to include the pharmacologically acceptable salts of formoterol.
• active compounds mentioned can also be present, for example, in the form of their solvates, in particular in the form of their hydrates.
• Suitable pharmacologically acceptable salts of roflumilast or formoterol are in particular water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)-benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 1-hydroxy-2-naphthoic acid, the acids being employed in salt preparation - depending on whether it is a mono- or polybasic acid and depending on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.
• Respiratory tract disorders which may be mentioned are in particular allergen- and inflammation- induced bronchial disorders (bronchitis, obstructive bronchitis, spastic bronchitis, allergic bronchitis, allergic asthma, bronchial asthma, COPD), which can be treated by the combination according to the invention also in the sense of a long-term therapy (if desired with appropriate adjustment of the dose of the individual components to the needs at the time, for example needs subject to seasonally related variations).
• allergen- and inflammation- induced bronchial disorders bronchitis, obstructive bronchitis, spastic bronchitis, allergic bronchitis, allergic asthma, bronchial asthma, COPD
• Combined use or “combination” within the meaning of the present invention is to be understood as meaning that the individual components can be administered simultaneously (in the form of a combination medicament), more or less simultaneously (from separate pack units) or in succession (directly in succession or else alternatively at a relatively large time interval) in a manner which is known per se and customary.
• one drug could be taken in the morning and one later in the day.
• one drug could be taken twice daily and the other once daily, either at the same time as one of the twice-a-day dosing occurred, or separately.
• Formoterol is usually administered as an oral or nasal spray or aerosol, or as an inhaled powder. Usually formoterol is not administered systemically or by injection. Roflumilast can be administered orally or by inhalation (orally or internasally). This invention contemplates either co-administering both drugs in one delivery form such as an inhaler, which is putting both drugs in the same inhaler. Alternatively one can put roflumilast into pills and package them in a medicament pack with an inhaler that contains formoterol.
• use can thus be understood as meaning primarily with respect to roflumilast the oral administration.
• formoterol orally in a lower dose, avoiding thus the known side effects of orally administered formoterol in higher doses.
• use is therefore, in accordance with the invention, understood primarily as meaning the oral administration, but it is also understood to mean topical application in inhalatory form.
• formoterol is preferably administered in the form of an aerosol, the aerosol particles of solid, liquid or mixed composition having a diameter of 0.5 to 10 ⁇ m, advantageously of 2 to 6 ⁇ m.
• Aerosol generation can be carried out, for example, by pressure-driven jet atomizers or ultrasonic atomizers, but advantageously by propellant-driven metered aerosols or propellant-free administration of micronized active compounds from inhalation capsules.
• the active compounds are dosed in an order of magnitude customary for the individual dose, it more likely being possible, on account of the individual actions, which are mutually positively influencing and reinforcing, to reduce the respective doses on the combined administration of the active compounds compared with the norm.
• formoterol is intended to be administered in a dose of preferably 10 to 50 ⁇ g per day by once, twice or three times daily administration.
• the administration forms additionally contain the required excipients, such as, for example, propellants (e.g. Frigen in the case of metered aerosols), surface-active substances, emulsifiers, stabilizers, preservatives, flavorings, fillers (e.g. lactose in the case of powder inhalers) or, if appropriate, further active compounds.
• propellants e.g. Frigen in the case of metered aerosols
• surface-active substances e.g. Frigen in the case of metered aerosols
• emulsifiers emulsifiers
• stabilizers emulsifiers
• preservatives e.g., emulsifiers, stabilizers, preservatives
• flavorings e.g. lactose in the case of powder inhalers
• fillers e.g. lactose in the case of powder inhalers
• the daily dose is in the range from 20 to 120 ⁇ g per day by once, twice or three times daily oral administration.
• the daily dose is in the range from 100 to 500 ⁇ g per day, preferably by once daily oral administration.
• the active ingredients roflumilast and/or formoterol are formulated to give medicaments according to processes known per se and familiar to the person skilled in the art.
• the active ingredients are employed as medicament, preferably in combination with suitable pharmaceutical excipients or vehicles, in the form of tablets, coated tablets, capsules, emulsions, suspensions or solutions, the active compound content advantageously being -between 0.1 and 95% and, by the appropriate choice of the excipients and vehicles, it being possible to achieve a pharmaceutical administration form precisely tailored to the active compound(s) and/or to the desired onset of action (e.g. a sustained-release form or an enteric form).
• formoterol is preferably formulated in such a way that it is released during a prolonged period of time.
• excipients or vehicles are suitable for the desired pharmaceutical formulations.
• solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or permeation promoters and complexing agents (e.g. cyclodextrins).
• OVA ovalbumin
• Sensitization was done by simultaneous injection of Borde- tella pertussis suspension i.p. and OVA/AHG suspension s.c. on day 1 , 14 and 21. 28 days after start of sensitization, conscious Brown-Norway rats were challenged by inhalation of the aerosolized OVA solution for 1 h ( ⁇ 20 ml/h). Non-challenged, only sensitized animals were used as baseline control.
• the drugs were administered intratra- cheally (i.t.) as dry powders 1 h before OVA-challenge. 48h later, OVA-challenged or non-challenged animals were anaesthetized and bronchoalveolar lavage (BAL) was performed using 3x4 ml BAL buffer per animal. The number of total cells and eosinophils in the BAL fluid, and the concentration of protein in the cell-free BAL fluid were determined. Drug-induced relative changes were calculated and statistically analyzed by the Jonckheere Terpstra test.
• the PDE inhibitor Roflumilast (PDE4 inhibitor) administered at a dose of 0.3 ⁇ mol/kg i.t. did not show any significant effects on cell infiltration and protein accumulation.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Pain & Pain Management (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicinal Preparation (AREA)

Priority Applications (21)

Applications Claiming Priority (2)

Publications (2)

Family

ID=32338002

Family Applications (1)

Country Status (31)

Cited By (4)

Families Citing this family (5)

Citations (7)

Family Cites Families (4)

• 2003
  • 2003-11-26 SI SI200331344T patent/SI1567139T1/sl unknown
  • 2003-11-26 UA UAA200505966A patent/UA83018C2/uk unknown
  • 2003-11-26 CN CNB2003801037450A patent/CN100346777C/zh not_active Expired - Fee Related
  • 2003-11-26 AT AT03767663T patent/ATE399543T1/de active
  • 2003-11-26 ME MEP-2008-782A patent/ME00489B/me unknown
  • 2003-11-26 MX MXPA05005437A patent/MXPA05005437A/es active IP Right Grant
  • 2003-11-26 RS YUP-2005/0382A patent/RS51081B/sr unknown
  • 2003-11-26 BR BR0316451-9A patent/BR0316451A/pt not_active IP Right Cessation
  • 2003-11-26 PT PT03767663T patent/PT1567139E/pt unknown
  • 2003-11-26 ES ES03767663T patent/ES2309357T3/es not_active Expired - Lifetime
  • 2003-11-26 AU AU2003292120A patent/AU2003292120B2/en not_active Ceased
  • 2003-11-26 JP JP2004554480A patent/JP2006508994A/ja active Pending
  • 2003-11-26 EA EA200500774A patent/EA009935B1/ru not_active IP Right Cessation
  • 2003-11-26 DK DK03767663T patent/DK1567139T3/da active
  • 2003-11-26 WO PCT/EP2003/013275 patent/WO2004047829A1/en not_active Ceased
  • 2003-11-26 US US10/535,816 patent/US20060142308A1/en not_active Abandoned
  • 2003-11-26 CA CA2506962A patent/CA2506962C/en not_active Expired - Fee Related
  • 2003-11-26 DE DE60321953T patent/DE60321953D1/de not_active Expired - Lifetime
  • 2003-11-26 HR HRP20050579AA patent/HRP20050579B1/hr not_active IP Right Cessation
  • 2003-11-26 PL PL377732A patent/PL216752B1/pl unknown
  • 2003-11-26 EP EP03767663A patent/EP1567139B1/en not_active Expired - Lifetime
  • 2003-11-26 NZ NZ540659A patent/NZ540659A/en not_active IP Right Cessation
  • 2003-11-26 KR KR1020057009210A patent/KR101071798B1/ko not_active Expired - Fee Related
• 2005
  • 2005-04-25 ZA ZA200503308A patent/ZA200503308B/en unknown
  • 2005-05-01 IL IL168308A patent/IL168308A/en not_active IP Right Cessation
  • 2005-05-10 TN TNP2005000131A patent/TNSN05131A1/en unknown
  • 2005-06-16 MA MA28343A patent/MA27539A1/fr unknown
  • 2005-06-17 NO NO20052999A patent/NO334247B1/no not_active IP Right Cessation
  • 2005-06-20 IS IS7898A patent/IS2575B/is unknown
  • 2005-06-27 CO CO05062787A patent/CO5690570A2/es not_active Application Discontinuation
• 2008
  • 2008-09-17 CY CY20081101017T patent/CY1110369T1/el unknown

Patent Citations (7)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events